.AstraZeneca has shared a very early consider the performance of its internal antibody-drug conjugat...
.After revealing a stage 3 launch based upon good midstage end results, iTeos and GSK are ultimately...
.The FDA needs to be much more open and also joint to release a rise in approvals of unusual disease...
.It is actually an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX as wel...
.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 test, but the biotec...
.Neurocrine Biosciences' schizophrenia course pivot has fallen short. The biotech was actually not a...
.Sanofi has actually brought in a late entry to the radioligand gathering, paying out one hundred th...
.After F2G's very first effort to obtain a new lesson of antifungal to market was actually thwarted ...
.Moderna has actually vowed to reduce R&D spending by $1.1 billion through 2027. The decision to ...
.Just 4 months after Sanofi bet $80 million in beforehand cash on Fulcrum Therapeutics' losmapimod, ...